Rxwire
In the news · 48h FDA 39 Eli Lilly 25 Roche 11 Merck & Co. (MSD) 9 Johnson & Johnson 8 Daiichi Sankyo 3 Bayer 2 Sanofi 2
Trials & R&D · first seen 1h ago, updated 1h ago

J&J, Legend tout long-term survival benefits for Carvykti in multiple myeloma

1 outlet Johnson & Johnson

Ten patients out of 20 who received Johnson & Johnson and Legend Biotech’s Carvykti remained alive at five years of follow up.

Summary from BioSpace - All News.

Coverage 1 article · 1 outlet

  1. BioSpace - All News
    J&J, Legend tout long-term survival benefits for Carvykti in multiple myeloma